{"title":"2型糖尿病药物上市","authors":"R. Mahajan, K. Gupta","doi":"10.5580/2417","DOIUrl":null,"url":null,"abstract":"Hyperglycemia, obesity, insulin resistance, dyslipidemia and hypertension are interrelated cardiometabolic risk factors for the development of type-2 diabetes and metabolic syndrome. Prevalence of type-2 diabetes is growing at an alarming rate. Treatment target for type-2 diabetes is to keep daily glucose profile as close as possible to that of a non-diabetic person. Sulfonylureas, thiazolidinediones, meglitinides, biguanides and acarbose inhibitors are already being used in controlling glucose levels in type-2 diabetes. This review discusses the new drugs with novel mechanism of actions; which are in pipeline and were marketed recently or will be in market in near future.","PeriodicalId":22523,"journal":{"name":"The Internet Journal of Pharmacology","volume":"71 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":"{\"title\":\"Drugs In Pipeline For Type-2 Diabetes\",\"authors\":\"R. Mahajan, K. Gupta\",\"doi\":\"10.5580/2417\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hyperglycemia, obesity, insulin resistance, dyslipidemia and hypertension are interrelated cardiometabolic risk factors for the development of type-2 diabetes and metabolic syndrome. Prevalence of type-2 diabetes is growing at an alarming rate. Treatment target for type-2 diabetes is to keep daily glucose profile as close as possible to that of a non-diabetic person. Sulfonylureas, thiazolidinediones, meglitinides, biguanides and acarbose inhibitors are already being used in controlling glucose levels in type-2 diabetes. This review discusses the new drugs with novel mechanism of actions; which are in pipeline and were marketed recently or will be in market in near future.\",\"PeriodicalId\":22523,\"journal\":{\"name\":\"The Internet Journal of Pharmacology\",\"volume\":\"71 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Internet Journal of Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5580/2417\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Internet Journal of Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5580/2417","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Hyperglycemia, obesity, insulin resistance, dyslipidemia and hypertension are interrelated cardiometabolic risk factors for the development of type-2 diabetes and metabolic syndrome. Prevalence of type-2 diabetes is growing at an alarming rate. Treatment target for type-2 diabetes is to keep daily glucose profile as close as possible to that of a non-diabetic person. Sulfonylureas, thiazolidinediones, meglitinides, biguanides and acarbose inhibitors are already being used in controlling glucose levels in type-2 diabetes. This review discusses the new drugs with novel mechanism of actions; which are in pipeline and were marketed recently or will be in market in near future.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
